Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PEPD | P12955 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | VHL | P40337 | 1/20 | 0.34 |
| ▸ | ELOC | Q15369 | 1/20 | 0.34 |
| ▸ | ELOB | Q15370 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611181 | 1.00 | ALDH1A1 (0.43) | ALDH1A1PEPDMMP2ANPEPCYP3A4 | |
| SCHEMBL9949422 | 0.85 | CHRM2 (0.36) | ALDH1A1CYP3A4MAPK1POLBVHL | |
| SCHEMBL9949420 | 0.85 | CHRM2 (0.36) | ALDH1A1CYP3A4MAPK1POLBVHL | |
| SCHEMBL542420 | 0.83 | MMP2 (0.42) | ALDH1A1PEPDMMP2ANPEPFKBP1A | |
| SCHEMBL18016774 | 0.83 | MMP2 (0.42) | ALDH1A1PEPDMMP2ANPEPFKBP1A | |
| SCHEMBL542421 | 0.83 | MMP2 (0.42) | ALDH1A1PEPDMMP2ANPEPFKBP1A | |
| SCHEMBL24141881 | 0.80 | MMP2 (0.56) | ALDH1A1MMP2ANPEPCYP3A4MAPT | |
| SCHEMBL1248327 | 0.80 | ATM (0.41) | VHLELOCELOB | |
| SCHEMBL8400039 | 0.80 | ALDH1A1 (0.47) | ALDH1A1PEPDMMP2ANPEPCYP3A4 | |
| SCHEMBL19900763 | 0.80 | ALDH1A1 (0.47) | ALDH1A1PEPDMMP2ANPEPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854786-B1 | METHOD FOR PRODUCING AMINO ACID DERIVATIVES | UBE CORP (JP) | 2026-02-18 | — | — | EP | disclosed |
| US-12281074-B2 | Method for producing amino acid derivatives | UBE CORPORATION (JP) | 2025-04-22 | — | — | US | disclosed |
| CN-119707784-A | Process for preparing amino acid derivatives | 株式会社API | 2025-03-28 | — | — | CN | disclosed |
| US-20250059191-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-02-20 | — | — | US | disclosed |
| US-12221443-B2 | Crystalline forms of diazabicyclooctane derivative and production process thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-02-11 | — | — | US | disclosed |
| CN-112930338-B | Process for preparing amino acid derivatives | 株式会社API | 2024-12-24 | — | — | CN | disclosed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| US-20240150292-A1 | METHOD FOR PRODUCING AMINO ACID DERIVATIVES | API CORPORATION (JP) | 2024-05-09 | — | — | US | disclosed |
| US-11897844-B2 | Method for producing amino acid derivatives | API CORPORATION (JP) | 2024-02-13 | — | — | US | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-9708320-B2 | β-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20160272641-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059191-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | CCNA1, RCC1, DDT | ALDH1A1 1981/4885PEPD 667/4885MMP2 2270/4885 |
| US-20160272641-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | DDT, CYP51A1, ODC1 | ALDH1A1 2440/4885PEPD 259/4885MMP2 2565/4885 |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, MRPL21, FNTB | ALDH1A1 502/4885PEPD 1445/4885MMP2 524/4885 |
| US-12221443-B2 | Crystalline forms of diazabicyclooctane derivative and production process thereof | CCNA1, RCC1, DDT | ALDH1A1 1981/4885PEPD 667/4885MMP2 2270/4885 |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, FN1, FNTB | ALDH1A1 466/4885PEPD 1634/4885MMP2 528/4885 |
| US-20240150292-A1 | METHOD FOR PRODUCING AMINO ACID DERIVATIVES | PTGS2, PTGES, PTGS1 | ALDH1A1 1128/4885PEPD 453/4885MMP2 3356/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | ALDH1A1 1362/4885PEPD 2053/4885MMP2 2248/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | ALDH1A1 1362/4885PEPD 2053/4885MMP2 2248/4885 |
| US-11897844-B2 | Method for producing amino acid derivatives | PTGS2, PTGES, PTGES2 | ALDH1A1 1057/4885PEPD 441/4885MMP2 3155/4885 |
| US-12281074-B2 | Method for producing amino acid derivatives | PTGS2, PTGES, PTGES2 | ALDH1A1 1057/4885PEPD 441/4885MMP2 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.